Inhibitors of fatty acid synthase (FASN), an enzyme involved in de novo fatty acid synthesis, have exhibited anti-tumor effects and enhanced sensitivity to chemotherapy in preclinical studies [7]. This evidence concerns the gene FASN and neoplasm.